Healthy people test new drug in Early-Stage study
NCT ID NCT07479576
First seen Mar 19, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This study tests a new drug called QL2106 against an approved drug, Tremfye®, in 190 healthy adults aged 18-45. The goal is to compare how the body processes each drug, their safety, and any immune reactions. Participants receive a single dose and are monitored closely. This is an early-phase study with no direct treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.